RT @brianfires: $VRX $AGN $HLF $IEP $TWTR $AAPL $MYL $MRK $KO $PEP $bac $SRPT
Absolutely Cruel That Insurance Cos. Won't Cover Treatment fo…
$VRX $AGN $HLF $IEP $TWTR $AAPL $MYL $MRK $KO $PEP $bac $SRPT
Absolutely Cruel That Insurance Cos. Won't Cover Trea… https://t.co/aYgejmdgDK
$VRX $AGN $HLF $IEP $TWTR $AAPL $MYL $MRK $KO $PEP $bac $SRPT
Anthem Has Been Covering Sarepta's Exondys51 For DMD https://t.co/mWtLxgnoiM
RT @run4mda: @realDonaldTrump DMD is a terminal disease w/only 1 FDA approved treatment. @AnthemInc is denying life-saving medicine to all…
Wondering about risks of $SRPT? The 63-day volatility is 28.57% https://t.co/w4uTHq3Rqa
$SRPT: Analyst action by Goldman Sachs on Sarepta Therapeutics: https://t.co/NHZcFXSuOg https://t.co/Ydz8Aa61gu
$SRPT analysis are all over the map yet all are way higher than current price. https://t.co/2U6h7y4Ncs
We calculated 63-day Expected Return of $SRPT for you: -49.22% https://t.co/3qjqhBJtqr
Explore #fundamental numbers and pros and cons for $SRPT https://t.co/39rt9KQRhU
Oppenheimer $SRPT Rare Diseases Launches, Always Complex We rate Sarepta (SRPT) Outperform with a $76 price (cont) https://t.co/fS092Xim9X
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
RT @run4mda: @realDonaldTrump DMD is a terminal disease w/only 1 FDA approved treatment. @AnthemInc is denying life-saving medicine to all…
Btw, Estimated #Earnings Per Share for $SRPT is $-0.6 it's -2.13% of the current price https://t.co/O4ZkIou3gJ
We calculated 21-day Expected Return of $SRPT for you: -22.08% https://t.co/3qjqhBJtqr
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
Learn how this Millionaire trader Creates more Millionaire Traders: https://t.co/OLOtvhiqFB $SRPT $YHOO $P $IYR
And again an example of a stock that fits this momentum with low volume pullback now is $SRPT a biotech $XBI $LABU https://t.co/5ijESwwMcl
Unicorn Bay rating for $SRPT is 2.15 out of 5. https://t.co/WtEDvqq4jN
RT @run4mda: @realDonaldTrump DMD is a terminal disease w/only 1 FDA approved treatment. @AnthemInc is denying life-saving medicine to all…
RT @OptionWhale: $SRPT Sarepta perfect example of low volume pullback, that my garbage man friend in NYC used to turn a $1000 into $1mn $MU…
RT @marketexclusive: Analyst Activity – JPMorgan Chase & Co. Initiates Coverage On Sarepta Therapeutics (NASDAQ:SRPT) With a O https://t.co…
RT @marketexclusive: Analyst Activity – JPMorgan Chase & Co. Initiates Coverage On Sarepta Therapeutics (NASDAQ:SRPT) With a O https://t.co…
RT @marketexclusive: Analyst Activity – JPMorgan Chase & Co. Initiates Coverage On Sarepta Therapeutics (NASDAQ:SRPT) With a O https://t.co…
RT @marketexclusive: Analyst Activity – JPMorgan Chase & Co. Initiates Coverage On Sarepta Therapeutics (NASDAQ:SRPT) With a O https://t.co…
RT @marketexclusive: Analyst Activity – JPMorgan Chase & Co. Initiates Coverage On Sarepta Therapeutics (NASDAQ:SRPT) With a O https://t.co…
RT @marketexclusive: Analyst Activity – JPMorgan Chase & Co. Initiates Coverage On Sarepta Therapeutics (NASDAQ:SRPT) With a O https://t.co…
Analyst Activity – JPMorgan Chase & Co. Initiates Coverage On Sarepta Therapeutics (NASDAQ:SRPT) With a O https://t.co/MPXt9VaNCM $SRPT
$SRPT: Analyst action by JP Morgan on Sarepta Therapeutics: https://t.co/ZGl06AmSL8 https://t.co/mwv0yeM0v5
Best biotech $XBI $IBB $LABU $LABD trade $SRPT Sarepta $JPM slaps $40 PT and low volume pullback at key support https://t.co/wiGHqk4UlV
$SRPT Sarepta perfect example of low volume pullback, that my garbage man friend in NYC used to turn a $1000 into $1mn $MU $AAPL $GDX $GLD
$JPM slaps $40 Price Target on $SRPT thats almost a 50% return for this biotech $XBI $IBB $LABU
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
Wondering about #sentiment indicator for $SRPT? The Short Ratio is 3.91% https://t.co/FaHj0s39f6
Wondering about risks of $SRPT? The 63-day volatility is 28.57% https://t.co/w4uTHq3Rqa
Sarepta Therap. Receives a Buy from Oppenheimer $SRPT https://t.co/q3bV4rFkVQ
@realDonaldTrump DMD is a terminal disease w/only 1 FDA approved treatment. @AnthemInc is denying life-saving medicine to all w/DMD!!! $srpt
RT @GantosJ: This report & Austin picture should be sent to all the jerks on the insurance con's who denied #Exondys51 for DMD boys & young…
Biotech buying opportunity? $SRPT https://t.co/we1iP2VNqg
RT @jennmcnary: $SRPT all who are amenable deserve access to #Exondys51 | https://t.co/l4nz9Nn1mv https://t.co/t643SlGxKk
RT @GantosJ: This report & Austin picture should be sent to all the jerks on the insurance con's who denied #Exondys51 for DMD boys & young…
RT @run4mda: @marcorubio insurance companies like Anthem should not be able to deny access to the only FDA approved treatment for DMD. Plea…
@marcorubio insurance companies like Anthem should not be able to deny access to the only FDA approved treatment for DMD. Please help! $srpt
RT @StunningFeline: $SRPT #EtepWorks #period time for insurance companies like @AnthemInc and @ExcellusBCBS to get on board https://t.co/fn…
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
$SRPT: Analyst action by JP Morgan on Sarepta Therapeutics: https://t.co/ZGl06AmSL8 https://t.co/qu0k2JfhwY
Do you know that #WallStreet price for $SRPT is $67.06 https://t.co/mJIZmTOUoc
RT @FajaJake: Muscular dystrophy patient: Insurance won't pay for breakthrough drug https://t.co/pw43H4ZEkW $SRPT
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
RT @jennmcnary: Meanwhile, @ExcellusBCBS thinks you need to walk to to benefit from $SRPT #Exondys51 https://t.co/yNs6ETtDxY
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
$srpt
Can't figure out why Jerry Lewis has nothing to say after this historic FDA approval of a drug to help his kids. Quite confounded.
https://t.co/qrAvxOgdCE // 9/19/16 Market Closing Summary // $SRPT #trading #investing #stocks https://t.co/L2alN7ojaR
$SRPT #EtepWorks #period time for insurance companies like @AnthemInc and @ExcellusBCBS to get on board https://t.co/fnkIfb1Xa5
RT @jennmcnary: Meanwhile, @ExcellusBCBS thinks you need to walk to to benefit from $SRPT #Exondys51 https://t.co/yNs6ETtDxY
We calculated 21-day Expected Return of $SRPT for you: -20.81% https://t.co/3qjqhBJtqr
RT @jennmcnary: Meanwhile, @ExcellusBCBS thinks you need to walk to to benefit from $SRPT #Exondys51 https://t.co/yNs6ETtDxY
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
RT @GantosJ: This report & Austin picture should be sent to all the jerks on the insurance con's who denied #Exondys51 for DMD boys & young…
Meanwhile, @ExcellusBCBS thinks you need to walk to to benefit from $SRPT #Exondys51 https://t.co/yNs6ETtDxY
Wow. $SRPT https://t.co/RK28qjb5xH
Friday: $ALXN, $DLTR, $BABA, $SGY, $JWN, $KSS, $NVDA, $EXPE, $SRPT
RT @GantosJ: This report & Austin picture should be sent to all the jerks on the insurance con's who denied #Exondys51 for DMD boys & young…
This report & Austin picture should be sent to all the jerks on the insurance con's who denied #Exondys51 for DMD b… https://t.co/641MbAlF50
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
RT @jennmcnary: $SRPT I don't believe I've ever seen a doctor report say #StableDuchenne #exondys51 https://t.co/XtnXLMtLOv
RT @megtirrell: We'll hear from one mom, @JettFoundation's Christine McSherry, on $SRPT case study panel at FDA-CMS Summit today! https://t…
RT @QTRResearch: $SRPT now just $1 from price it was at prior to FDA approval
RT @_B_I_O_T_E_C_H_: rbc $srpt EXONDYS 51 utilization survey: it's a slow start, but docs willing to use it widely Our view: In (cont) http…
RT @StunningFeline: $SRPT RBC survey says Drs have already placed 333 pts in Exondsy 51. Crushing all projections!!!! https://t.co/xiHf5zGy…
RT @dpreda: #Biotech buying opportunity? $CELG $GILD $BIIB $JUNO $SRPT $FGEN $ALDR $ICPT $AMGN $IONS #health #epigenetics https://t.co/5rw…